FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Meswani Parag V 2. Issuer Name and Ticker or Trading Symbol Sio Gene Therapies Inc. [ SIOX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Commercial Officer
(Last)         (First)         (Middle)
C/O SIO GENE THERAPIES INC., 130 W. 42ND ST., 26TH FL.
3. Date of Earliest Transaction (MM/DD/YYYY)
2/8/2022
(Street)
NEW YORK, NY 10036
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units   (1) 2/8/2022    A     153700       (2)  (2) Common Stock  153700.0  $0  153700  D   

Explanation of Responses:
(1)  Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
(2)  One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Meswani Parag V
C/O SIO GENE THERAPIES INC.
130 W. 42ND ST., 26TH FL.
NEW YORK, NY 10036


Chief Commercial Officer

Signatures
/s/ David Nassif, Attorney-in-Fact 2/10/2022
**Signature of Reporting Person Date
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Axovant Gene Therapies Charts.
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Axovant Gene Therapies Charts.